Review article · 1 Oct 2019
Conference abstractPublished 1 Apr 2021
Biosimilar Drug Development and Approval Process
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Emphasis will be placed on a stepwise approach to provide analytical studies, biological characterization, preclinical and clinical testing of the proposed biosimilar product presented in the premarket applications.The sponsors of premarket applications must present analytical characterization, pharmacokinetic (PK), pharmacodynamic (PD) and comparative clinical studies to demonstrate that a proposed biosimilar product is highly similar to a licensed reference product.Discussions will be presented on Quality Systems approach to c-GMP’s for Biosimilar Applications (Design Controls, validation and verification studies, analytical similarity, manufacturing and effective total product life-cycle CMC strategy).Discussions will be presented on clinical aspects of proposed biosimilar product (Immunogenicity Assessment, Extrapolations & Interchangeability in conformance with specific recommendations described in the FDA’s guidance on biosimilar labeling) Emphasis will be placed on Quality Risk Management approach to design of studies by providing oversight and objective review of risk-benefit analysis that guides the clinical use of the new biosimilar drug product by providing patients organized data and appropriate labeling information in support of the new drug’s intended clinical use. PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 30 Sep 2024
Clinical Trials and Regulatory Approvals: Navigating the Drug Development Process
Research article · 24 Jun 2015
From Idea to Market: The Drug Design, Development & Approval Process
Conference abstract · 26 Oct 2015
CMC Consideration for Biosimilar Drug Development and Manufacturing Process
Perspective · 28 Dec 2024
Drug Regulation and Approval: Impact of Accelerated Processes in the COVID Era
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kaiser J Aziz”
